P. Moriarty

P. Moriarty, J. Backes, Janelle F Ruisinger, 2018, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Statin-associated muscle symptoms-Managing the highly intolerant.

C. Gibson, P. Moriarty, J. Backes, 2017, Journal of clinical lipidology.

The high-dose rosuvastatin once weekly study (the HD-ROWS).

C. Gibson, P. Moriarty, J. Backes, 2011, Journal of clinical lipidology.

Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance.

C. Gibson, P. Moriarty, J. Backes, 2009, The American journal of cardiology.

Statin Intolerance and Vitamin D Supplementation: Sunny, but a Few Clouds Remain…

P. Moriarty, Brian J. Barnes, J. Backes, 2015, North American journal of medical sciences.

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

F. Kronenberg, A. von Eckardstein, M. Koschinsky, 2022, European heart journal.

Pseudohypertriglyceridemia: two cases of probable glycerol kinase deficiency.

T. Dayspring, P. Moriarty, J. Backes, 2012, Journal of clinical lipidology.

Comparison of Different Low Density Lipoprotein Apheresis Machines on Brain Natriuretic Peptide Levels in Patients With Familial Hypercholesterolemia

J. Belmont, R. Sosland, C. Gibson, 2010, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

A Phase 3 Randomized Trial Evaluating Alirocumab 300 mg Every 4 Weeks (Q4W) as Monotherapy or Add-On to Statin: ODYSSEY CHOICE I

D. Rader, J. Bergeron, P. Moriarty, 2016 .

The presence of an intron within the rat gene for selenium-dependent glutathione peroxidase 1 is not required to protect nuclear RNA from UGA-mediated decay.

L. Maquat, C. C. Reddy, P. Moriarty, 1997, RNA.

Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes.

Deepak L. Bhatt, R. Diaz, H. White, 2022, Journal of clinical lipidology.

Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease.

Jessica V. Gray, P. Moriarty, L. Gorby, 2019, Journal of clinical lipidology.

Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension

R. Santos, J. Guyton, P. Duell, 2013, European heart journal.

The use of lipopheresis in the practice of clinical lipidology.

R. Brook, L. Hemphill, W. Brown, 2012, Journal of clinical lipidology.

A comparison of 25-hydroxyvitamin D serum levels among those with or without statin-associated myalgias.

P. Moriarty, Brian J. Barnes, J. Backes, 2011, Atherosclerosis.

Lipoprotein Apheresis: First FDA Indicated Treatment for Elevated Lipoprotein(a)

Jessica V. Gray, P. Moriarty, Anne K. Nugent, 2020 .

Effect of low-density lipoprotein cholesterol apheresis on blood viscosity.

K. Kensey, C. Gibson, W. Hogenauer, 2004, The American journal of cardiology.

Lipid-Lowering Therapy and Apheresis: Indications and Outcomes

P. Moriarty, Audrey E. McCalley, 2015 .

Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Jennifer G. Robinson, S. Daniels, D. Rader, 2011, Journal of clinical lipidology.

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

D. Gaudet, R. Hegele, E. Steinhagen-Thiessen, 2021, The lancet. Diabetes & endocrinology.

Large Clinical Trials of Statin-Associated Muscle Symptoms

P. Moriarty, 2020 .

JCL roundtable: PCSK9 inhibitors in clinical practice.

J. Mckenney, W. Brown, P. Moriarty, 2016, Journal of clinical lipidology.

Effect of low-density lipoprotein apheresis on plasma levels of apolipoprotein e4.

J. Luyendyk, C. Gibson, P. Moriarty, 2010, The American journal of cardiology.

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

Deepak L. Bhatt, P. López-Jaramillo, R. Diaz, 2019, Circulation.

Comparing patients' prescribed, self-reported, and actual intake of supplemental eicosapentaenoic acid + docosahexaenoic acid.

B. Melton, P. Moriarty, J. Backes, 2019, Journal of clinical lipidology.

Therapeutic Plasma Exchange for the Treatment of Systemic Scleroderma : A Comprehensive Review and Analysis

H. Meiselman, P. Moriarty, E. S. Harris, 2016 .

Successful long-term (22 year) treatment of limited scleroderma using therapeutic plasma exchange: Is blood rheology the key?

H. Meiselman, P. Moriarty, E. S. Harris, 2017, Clinical hemorheology and microcirculation.

Effect of low-density lipoprotein apheresis on lipoprotein-associated phospholipase A2.

C. Gibson, P. Moriarty, 2005, The American journal of cardiology.

National heart, lung, and blood institute state of the science symposium in therapeutic apheresis—Therapeutic apheresis in cardiovascular disease

J. Winters, P. Moriarty, Yanyun Wu, 2015, Journal of clinical apheresis.

JCL roundtable-Lipoprotein(a): The emerging risk factor.

M. Koschinsky, S. Marcovina, J. Guyton, 2018, Journal of clinical lipidology.

Lp(a) and Cardiovascular Outcomes: an Analysis from the ODYSSEY OUTCOMES Trial

Deepak L. Bhatt, R. Diaz, H. White, 2018, Atherosclerosis Supplements.

Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics: Implications for Precision Medicine—Brief Report

C. Ballantyne, S. Virani, Matthew R. Deshotels, 2022, Arteriosclerosis, thrombosis, and vascular biology.

Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol.

J. Belmont, I. Opole, P. Moriarty, 2007, The American journal of cardiology.

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

M. Banach, N. Wong, K. Kostner, 2015, Expert opinion on drug safety.

Apolipoprotein C-III Inhibition with Volanesorsen in Patients with Hypertriglyceridemia (COMPASS): a Randomized, Double-Blind, Placebo-controlled Trial

D. Gaudet, E. Steinhagen-Thiessen, I. Gouni-Berthold, 2017, Atherosclerosis Supplements.

Optimizing Cholesterol Treatment in Patients With Muscle Complaints.

M. Banach, G. Watts, P. Thompson, 2017, Journal of the American College of Cardiology.

Association of ApoE and HDL.C with cardiovascular and cerebrovascular disease: potential benefits of LDL-apheresis therapy

P. Moriarty, 2009 .

Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Matthew K. Ito, P. Moriarty, M. McGowan, 2011, Journal of clinical lipidology.

Important Considerations for Treatment with Dietary Supplement versus Prescription Niacin Products

P. Moriarty, R. Padley, J. Backes, 2011, Postgraduate medicine.

Selenium Deficiency Reduces the Abundance of mRNA for Se-Dependent Glutathione Peroxidase 1 by a UGA-Dependent Mechanism Likely To Be Nonsense Codon-Mediated Decay of Cytoplasmic mRNA

L. Maquat, C. C. Reddy, P. Moriarty, 1998, Molecular and Cellular Biology.

Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study

A. Feinstein, P. Moriarty, V. Devonshire, 2016, BMC Research Notes.

Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs.

G. Watts, K. Widhalm, M. Harada‐Shiba, 2017, Journal of clinical lipidology.

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial.

P. Thompson, E. Bruckert, J. Guyton, 2014, Journal of clinical lipidology.

Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study.

T. Sampietro, C. Kurtz, B. Hohenstein, 2019, Journal of clinical lipidology.

Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry.

Emily C. O'Brien, J. Knowles, D. Rader, 2017, Atherosclerosis.

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.

S. Humphries, S. Yamashita, G. Watts, 2016, The lancet. Diabetes & endocrinology.

Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry

Emily C. O'Brien, J. Knowles, D. Rader, 2016, Circulation. Cardiovascular genetics.

Managing the challenging homozygous familial hypercholesterolemia patient: Academic insights and practical approaches for a severe dyslipidemia, a National Lipid Association Masters Summit.

A. Goldberg, G. Hovingh, P. Moriarty, 2017, Journal of clinical lipidology.

The effects of mipomersen, a secondgeneration antisense oligonucleotide, on atherogenic (apoB-containing) lipoproteins in the treatment of homozygous familial hypercholesterolemia

P. Moriarty, M. McGowan, J. Backes, 2014 .

Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)

A. Khera, D. Panagiotakos, J. Jozwiak, 2022, Journal of cachexia, sarcopenia and muscle.

The Role of Nutraceuticals in Statin Intolerant Patients.

D. Panagiotakos, B. Paulweber, A. Sahebkar, 2018, Journal of the American College of Cardiology.

Identifying pseudohypertriglyceridemia in clinical practice

T. Dayspring, J. Mcconnell, J. Contois, 2014 .

Maquat of Cytoplasmic mRNA Likely To Be Nonsense Codon-Mediated Decay Peroxidase 1 by a UGA-Dependent Mechanism of mRNA for Se-Dependent Glutathione Selenium Deficiency Reduces the Abundance

C. C. Reddy, P. Moriarty, E. Lynne, 1998 .

A phase 2 trial of the efficacy and safety of evinacumab in patients with severe hypertriglyceridemia

D. Gaudet, D. Rader, C. Ballantyne, 2021, Atherosclerosis.

Nonsense-mediated decay of mRNA for the selenoprotein phospholipid hydroperoxide glutathione peroxidase is detectable in cultured cells but masked or inhibited in rat tissues.

L. Maquat, X. Li, L E Maquat, 2001, Molecular biology of the cell.

Nonsense‐mediated decay of glutathione peroxidase 1 mRNA in the cytoplasm depends on intron position

L. Maquat, P. Moriarty, Xiaolei Sun, 2000, The EMBO journal.

Role of C-Reactive Protein in Cardiovascular Disease

P. Moriarty, P. Howard, J. Backes, 2004, The Annals of pharmacotherapy.

Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal.

M. Boffa, M. Koschinsky, G. Watts, 2018, Journal of clinical lipidology.

Low‐Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events

P. Willeit, S. Tsimikas, J. Mcconnell, 2020, Journal of the American Heart Association.

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.

Deepak L. Bhatt, R. Diaz, H. White, 2020, Journal of the American College of Cardiology.

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

M. Banach, N. Wong, K. Kostner, 2015, Expert opinion on drug safety.

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

Saptarsi M. Haldar, S. Melquist, G. Watts, 2022, Nature Medicine.

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

Saptarsi M. Haldar, S. Melquist, Hong Wang, 2022, Nature Medicine.

Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study

M. Beudel, B. H. van den Born, S. Tsimikas, 2021, Atherosclerosis.

Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis

J. Kastelein, E. Stroes, S. Tsimikas, 2020, Current Atherosclerosis Reports.

Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin.

D. Johns, D. Kirchhofer, J. Luyendyk, 2012, The Journal of clinical investigation.

CHAPTER 30 – Low-Density Lipoprotein Apheresis

P. Moriarty, 2009 .

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

D. Gaudet, D. Rader, C. Ballantyne, 2023, Nature Medicine.

Familial Hypercholesterolemia and Lipid Apheresis

C. Gibson, P. Moriarty, K. Flechsenhar, 2007 .

Lipoprotein apheresis.

L. Hemphill, P. Moriarty, 2015, Cardiology clinics.

Fibrates: What Have We Learned in the Past 40 Years?

C. Gibson, P. Moriarty, J. Backes, 2007, Pharmacotherapy.

Apheresis therapy for retinal vasculitis.

P. Moriarty, T. Whittaker, 2007, Archives of ophthalmology.

Apple pectin for the reduction of niacin-induced flushing.

P. Moriarty, Jianghua He, J. Backes, 2013, Journal of clinical lipidology.

Clinical pharmacologic concepts for the rational selection and use of drugs for the management of dyslipidemia.

C. Dujovne, P. Moriarty, 1996, Clinical therapeutics.

Jennifer G. Robinson, S. Daniels, D. Rader, 2011, Journal of clinical lipidology.

Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins

J. Miles, P. Moriarty, A. Anabtawi, 2017, Current Cardiology Reports.

Relative risk reduction versus number needed to treat as measures of lipid-lowering trial results.

P. Moriarty, 1998, The American journal of cardiology.

Statins and almonds to lower lipoproteins (the STALL Study).

Bryan K. Smith, P. Kris-Etherton, D. Sullivan, 2015, Journal of clinical lipidology.

Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP).

A. Sahebkar, M. Banach, M. Rizzo, 2023, Pharmacological research.

Evaluating the Effects of Prescription Fish Oil, Supplemental Fish Oil and a Krill Oil Blend on Serum Lipids/Lipoproteins and the Omega-3 Index: A Pilot Study

C. Gibson, P. Moriarty, Harris Ws, 2014 .

Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia.

D. Gaudet, J. Tardif, C. Ballantyne, 2022, Journal of clinical lipidology.

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

P. Thompson, E. Steinhagen-Thiessen, M. Cornier, 2016, European heart journal.

Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients.

G. Lip, A. Sahebkar, M. Banach, 2015, International journal of cardiology.

Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis

M. Pencina, M. Banach, D. Mikhailidis, 2017, Cardiovascular Drugs and Therapy.

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.

D. Grobbee, P. Thompson, J. Kastelein, 2023, The New England journal of medicine.

Effectiveness and Tolerability of Every-Other-Day Rosuvastatin Dosing in Patients with Prior Statin Intolerance

P. Thompson, C. Gibson, P. Moriarty, 2008, The Annals of pharmacotherapy.

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.

C. Cannon, P. Thompson, E. Bruckert, 2015, Journal of clinical lipidology.

Interleukin-1β Induces Calcium Transients and Enhances Basal and Store Operated Calcium Entry in Human Myometrial Smooth Muscle1

L. Poston, P. Moriarty, R. Tribe, 2003, Biology of reproduction.

Does Simvastatin Cause More Myotoxicity Compared with Other Statins?

P. Moriarty, P. Howard, J. Backes, 2009, The Annals of pharmacotherapy.

Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society.

F. Kronenberg, M. Koschinsky, G. Watts, 2023, Atherosclerosis.

Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry

J. Knowles, D. Rader, C. Ballantyne, 2023, Journal of the American Heart Association.

Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study.

D. Capuzzi, H. Bays, Shuiping Zhao, 2014, Journal of clinical lipidology.

Homogeneity of treatment effect of REGN727/SAR236553, a fully human monoclonal antibody against PCSK9, in lowering LDL-C: data from three phase 2 studies

P. Moriarty, R. Pordy, C. Hanotin, 2013 .

Long-Term Safety and Efficacy of Mipomersen in Patients with Familial Hypercholesterolemia Uncontrolled by Maximally Tolerated Lipid Lowering Therapy

R. Santos, J. Guyton, P. Duell, 2012 .

Classical selenium-dependent glutathione peroxidase expression is decreased secondary to iron deficiency in rats.

J. Beard, C. C. Reddy, P. Moriarty, 1995, The Journal of nutrition.

A Comparison of Patients’ Prescribed, Self-Reported, and Actual Intake of Supplemental EPA/DHA

B. Melton, P. Moriarty, J. Backes, 2016 .

Abstract 12169: LDL-C Levels and Treatment Patterns Among Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry

J. Knowles, D. Rader, C. Ballantyne, 2015 .

Lipoprotein-X disease in the setting of severe cholestatic hepatobiliary autoimmune disease.

L. Sperling, P. Moriarty, R. Heinl, 2017, Journal of clinical lipidology.

Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles

D. Gaudet, R. Hegele, E. Bruckert, 2019, Journal of the Endocrine Society.

Supratherapeutic Response to Ezetimibe in a Statin Intolerant Patient

P. Moriarty, J. Backes, Janelle F. Ruisinger, 2010 .

Variability in Potency Among Commercial Preparations of Berberine

R. Singh, S. Kandel, R. Winefield, 2018, Journal of dietary supplements.

Utility of the Canadian Treatment Optimization Recommendations (TOR) in MS Care

A. Traboulsee, M. Freedman, F. Grand'Maison, 2013, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Recommendations criteria for determining level of concern for patients with changes in relapse , disease progression and MRI outcomes ( adapted with permission from

A. Traboulsee, M. Freedman, F. Grand'Maison, 2013 .

The First Case Report of the Treatment of Transplant Coronary Artery Disease With Dextran Sulfate Adsorption Lipid Apheresis

R. Sosland, David B. Wilson, P. Moriarty, 2010, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

First on-line survey of an international multidisciplinary working group (MightyMedic) on current practice in diagnosis, therapy and follow-up of dyslipidemias.

M. Harada‐Shiba, H. Soran, U. Julius, 2015, Atherosclerosis. Supplements.

Efficacy and safety of the PCSK9 inhibitor alirocumab 300 mg every 4 weeks in patients with ASCVD.

D. Rader, J. Bergeron, P. Moriarty, 2017, Atherosclerosis.

Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study

Anthony Feinstein, A. Feinstein, Virginia A. Devonshire, 2016, BMC Research Notes.

Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)

M. Safarova, P. Moriarty, 2023, Current Atherosclerosis Reports.

Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry.

Emily C. O'Brien, J. Knowles, D. Rader, 2014, American heart journal.

The Role of Nutraceuticals in Statin Intolerant Patients.

D. Panagiotakos, B. Paulweber, A. Sahebkar, 2018, Journal of the American College of Cardiology.

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.

D. Rader, M. Koschinsky, M. Olive, 2018, Journal of the American College of Cardiology.

Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics: Implications for Precision Medicine—Brief Report

C. Ballantyne, S. Virani, Vijay Nambi, 2022, Arteriosclerosis, thrombosis, and vascular biology.

Abstract 15281: Triglyceride Levels and Cardiovascular Outcomes After Acute Coronary Syndrome: Insights From the Odyssey Outcomes Trial

Deepak L. Bhatt, R. Diaz, H. White, 2020 .

Abstract 13951: Safety, Tolerability and Efficacy of Single-dose Amg 890, a Novel Sirna Targeting Lp(a), in Healthy Subjects and Subjects With Elevated Lp(a)

G. Watts, Huei Wang, M. Koren, 2020, Circulation.

Pseudohypertriglyceridemia: two cases of probable glycerol kinase deficiency.

T. Dayspring, P. Moriarty, J. Backes, 2012, Journal of clinical lipidology.

Lipoprotein apheresis.

L. Hemphill, P. Moriarty, 2015, Cardiology clinics.

Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial

Pedro F. Campos, Luciano Lopes de Sousa, Howard D. Rubenstein, 2023, European heart journal.